Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

BioCentury | Jan 6, 2014
Clinical News

AXL1717: Final Phase II data

BioCentury | Dec 27, 2013
Clinical News

Axelar's AXL1717 misses in Phase II NSCLC trial

BioCentury | Apr 8, 2013
Clinical News

AXL1717: Interim Phase II data

BioCentury | Jan 28, 2013
Clinical News

AXL1717: Phase I/II started

BioCentury | Jan 2, 2012
Clinical News

AXL1717: Phase II started

BioCentury | Oct 10, 2011
Clinical News

AXL1717: Additional Phase I/II data

BioCentury | Apr 18, 2011
Clinical News

AXL1717: Interim Phase I/II data

BioCentury | Sep 13, 2010
Clinical News

AXL1717: Phase I/II data

BioCentury | May 18, 2009
Clinical News

AXL1717: Phase I/II data

Items per page:
1 - 10 of 11